1. Scrip

Eight COVID-19 Vaccines Approved In India In 2021, mRNA Addition Awaited

 
• By Vibha Ravi

While an mRNA vaccine is still missing, 2021 saw Indian companies strike alliances, battle legal action and gain funding while the regulator played a crucial enabling role in the run up to the approval of eight COVID-19 vaccines from zero in 2020.

Vaccines
The 2021 Spotlight Was On COVID-19 Vaccines • Source: Alamy

Just as 2021 was drawing to a close, the Drugs Controller General of India gave approval for restricted use in emergency situation to COVID-19 vaccines from Novavax, Inc. partner Serum Institute of India Pvt. Ltd. and Baylor College of Medicine partner Biological E. Ltd.

India got its first two coronavirus vaccines in January 2021 and with four others approved during the course of last year, the tally stood at eight

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.